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ABSTRACT
Glyoxal and methylglyoxal are reactive dicarbonyl
metabolites formed and metabolized in physiologic-
al systems. Increased exposure to these
dicarbonyls is linked to mutagenesis and cytotox-
icity and enhanced dicarbonyl metabolism by
overexpression of glyoxalase 1 is linked to tumour
multidrug resistance in cancer chemotherapy. We
report herein that glycation of DNA by glyoxal and
methylglyoxal produces a quantitatively important
class of nucleotide adduct in physiological
systems—imidazopurinones. The adduct derived
from methylglyoxal-3-(20-deoxyribosyl)-6,7-dihydro-
6,7-dihydroxy-6/7-methylimidazo-[2,3-b]purine-9(8)-
one isomers—was the major quantitative adduct
detected in mononuclear leukocytes in vivo and
tumour cell lines in vitro. It was linked to frequency
of DNA strand breaks and increased markedly
during apoptosis induced by a cell permeable
glyoxalase 1 inhibitor. Unexpectedly, the DNA
content of methylglyoxal-derived imidazopurinone
and oxidative marker 7,8-dihydro-8-oxo-
20-deoxyguanosine were increased moderately in
glyoxalase 1-linked multidrug resistant tumour cell
lines. Together these findings suggest that
imidazopurinones are a major type of endogenous
DNA damage and glyoxalase 1 overexpression in
tumour cells strives to counter increased
imidazopurinone formation in tumour cells likely
linked to their high glycolytic activity.
INTRODUCTION
Guanyl bases of nucleotides and nucleosides are suscep-
tible to modiﬁcation by glyoxal and methylglyoxal (1).
Glyoxal and methylglyoxal react with deoxyguanosine
under physiological conditions to form mainly
imidazopurinone derivatives, 3-(20-deoxyribosyl)-6,7-
dihydro-6,7-dihydroxyimidazo[2,3-b]purin-9(8)one (GdG)
and 3-(20-deoxyribosyl)-6,7-dihydro-6,7-dihydroxy-6/7-
methylimidazo-[2,3-b]purine-9(8)one (MGdG)—a 6- and
7-methyl structural isomeric mixture, respectively (2)
(Figure 1a). Glyoxal and methylglyoxal also form
N2-carboxymethyl-deoxyguanosine (CMdG) (3) and
N2-(1,R/S-carboxyethyl)-deoxyguanosine (CEdG)—the
latter a stereoisomeric mixture of R/S-epimers at the
N2-1-carboxyethyl chiral centre (4). Glyoxal and
methylglyoxal are formed in physiological systems:
glyoxal is formed by lipid peroxidation and also by deg-
radation of glycated proteins and monosaccharides;
methylglyoxal is formed mainly by non-enzymatic deg-
radation of triosephosphates and is also formed by
ketone body metabolism and threonine catabolism.
Increased methylglyoxal formation occurs in cells with
high glycolytic activity. Many tumours have high
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glycolytic activity which is thought to be a survival adap-
tation to growth under hypoxic conditions (5,6).
Detection of imidazopurinones derived from glyoxal
and methylglyoxal in cellular DNA in vitro and in vivo
has proven generally elusive to date. There has been
extensive research quantifying the level of the
dG-derived oxidative marker 8-oxo-7,8-dihydro-
20-deoxyguanosine (8-OxodG) nucleotides in DNA and
related nucleosides released into plasma and excreted
in urine (7), as well as other trace endogenous dG
adducts (8). There have also been some reports on the
minor methylglyoxal-derived nucleotide adduct CEdG
(9) and a recent report on the minor glyoxal-derived
adduct CMdG (10). Failure to detect imidazopurinones
in cell systems may have been due to poor adduct stability
and recovery in pre-analytic processing of analytical
protocols.
Dicarbonyl adducts of DNA are of likely functional
importance because glyoxal and methylglyoxal are both
weak mutagens. Diseases associated with high plasma
levels of dicarbonyls—diabetes and renal failure—are
also associated with increased mutagenicity, cancer risk
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Figure 1. (a) Formation of glycation and oxidation adducts of deoxyguanosine. The common 20-deoxyribosyl group has been omitted for clarity.
(b) The glyoxalase pathway.
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and vascular cell apoptosis (11). Protection against
dicarbonyl mutagenicity and cytotoxicity is provided
mainly by the glutathione-dependent cytosolic glyoxalase
system. The glyoxalase system is comprised of glyoxalase 1
(Glo1), glyoxalase 2 (Glo2) and a catalytic amount of
glutathione. Glo1 catalyses the detoxiﬁcation of glyoxal
and methylglyoxal to S-glycolylglutathione and S-D-
lactoylglutathione, respectively, and Glo2 catalyses the
hydrolysis of these glutathione thioesters to glycolate
and D-lactate, reforming glutathione consumed by Glo1
(Figure 1b) (12). In 2000, Tsuruo and co-workers (13)
discovered overexpression of Glo1 as a novel factor
producing multidrug resistance (MDR) in tumours.
Glo1-linked MDR was found in tumour cells of lung,
colorectal, breast and prostate origin, was acquired by
experimental Glo1 overexpression and could be countered
by the cell permeable Glo1 inhibitor S-p-bromobenzyl-
glutathione cyclopentyl diester (BBGD) (14)—an experi-
mental cancer chemotherapeutic agent (15).
In this report, we describe the concurrent quantitation
of imidazopurinones, GdG and MGdG, and CEdG and
8-OxodG by stable isotopic dilution analysis liquid chro-
matography with tandem mass spectrometric detection
(LC-MS/MS) in physiological samples and explore the
link of levels of imidazopurinone adducts to DNA
strand breaks and Glo1-associated MDR in human
tumour cell lines.
MATERIALS AND METHODS
Materials
20-Deoxyguanosine monohydrate and glyoxal and
methylglyoxal solutions (40%), ribonuclease (RNase) A
from bovine pancreas, RNase T1 from Aspergillus
oryzae, deoxyribonuclease (DNase) II from porcine
spleen, phosphodiesterase (PDE) II from bovine spleen,
acid phosphatase from potato were purchased from
Sigma (Poole, Dorset, UK). Protease was from Qiagen.
[13C10,
15N5]-2
0-deoxyguanosine (all >98% isotopic
purity) was purchased from Cambridge Isotope
Laboratories (Andover, MA, USA). GdG, MGdG and
related stable isotopic standards were prepared as
described earlier (16). CEdG was conveniently prepared
from the crude product mixture of MGdG by addition
of 10mM phosphate buﬀer, adjustment of the pH to7.4
and continued incubation at 37C for 6 days—the MGdG
therein degrading in part to CEdG. CEdG was puriﬁed
by preparative anion exchange HPLC on DEAE
Protein-Pak, formate form (2 10 cm column; Waters);
sample loading 20mg. The column was equilibrated and
eluted isocratically for 10min with 5mM ammonium
formate buﬀer, pH 4.0, and then with a linear gradient
of 5–100mM of the same buﬀer from 10–45min; the
ﬂow rate was 4ml/min. Fractions were analysed by
LC-MS/MS (see below) and those containing CEdG
were lyophilized to dryness and analysed by 1H and 13C
NMR and mass spectrometry. Analytical characteristics
were as reported previously (9,17). The preparation con-
tained an equal mixture of S- and R-epimers.
Isolation of DNA from cell samples
Human mononuclear leukocytes, isolated from venous
blood by density gradient centrifugation of the buﬀy
coat (18), or human tumour cells grown in culture
(5–30 106 cells), were washed three times in phosphate
buﬀered saline and re-suspended in 2ml lysis buﬀer
(320mM sucrose, 10mM Tris/HCl, 5mM MgCl2,
100 mM desferroxamine [DFOM], 1% Triton X-100, pH
7.5) and kept on ice for 20min to swell. Cells were then
lysed by vigorous agitation (three cycles of 5min vortexing
followed by 5min on ice). Nuclei were collected by centri-
fugation (1500g, 10min, 4C), washed with 2ml lysis
buﬀer (1500g, 10min, 4C) and stored at 80C at this
step until further processing. The sedimented nuclei were
re-suspended in 1.2ml nuclear lysis buﬀer (10mM
Tris/HCl, 5mM EDTA, 150mM DFOM and 50 ml 10%
SDS, pH 8.0) and left on ice for 20min. The nuclei were
lysed by three cycles of vortexing (as described earlier),
40 ml RNase A (1mg/ml) and 15 ml RNase T1 (1 kU/ml)
added and incubated for 15min at 50C. Protease (20mg/
ml; 40 ml) was added and samples were incubated for 2 h at
37C. DNA was precipitated by addition of 3ml NaI
solution (7.6M NaI, 40mM Tris/HCl, 20mM EDTA
and 300 mM DFOM, pH 8.0) and 4ml 2-propanol at
4C. Precipitation was promoted by inversion of the
sample tube 5–10 times. The emergent DNA strand was
collected from solution on a spooler, transferred to a
microcentrifuge tube and washed twice with 2ml of 40%
2-propanol and then twice with 2ml 70% ethanol at 4C.
The resulting DNA pellet was dried under argon to
remove the remaining ethanol and re-dissolved in
argon-saturated water containing 200 mM DFOM,
assisted by sample rotary inversion for 24 h at 4C in the
dark. The concentration of the DNA in the sample was
determined by UV nanodrop spectrophotometry at
260 nm by diluting an aliquot (2 ml) 50-fold in buﬀer
(10mM Tris/HCl, 1mM EDTA and 200mM DFOM,
pH 7.4). Genomic DNA was stored at 4C overnight or
80C for the longer periods.
Digestion of DNA
Genomic DNA was washed into 83mM ammonium
acetate buﬀer, containing 8.3mM MgSO4, 20mM
NH4Cl, 500mM aminoguanidine hydrochloride and
100 mM DFOM, pH 5.0, by three cycles of concentration
to 100 ml and dilution to 500 ml with buﬀer in microspin
ultraﬁlters (10 kDa cut-oﬀ, Nanosep, low binding poly-
propylene) at 4C. DNA (25mg in 30 ml buﬀer) was
digested by addition of 2 ml of DNase II (2U/mg DNA)
and 2 ml PDE II (1.5U/mg DNA). Samples were ﬂushed
with argon and incubated at 37C for a further 30min.
Acid phosphatase (type VII, 10 ml; 35 U/mg DNA) was
then added, samples again ﬂushed with argon and
incubated at 37C for a further 4 h. Enzymes were then
removed from the sample by ultraﬁltration (10 kDa cut-oﬀ
microspin ﬁlter, 4C). Analytical recoveries were per-
formed by splitting extracted DNA into multiple
aliquots and spiking half of the samples with standard
analyte prior to digestion and comparing this amount
with the analyte increment detected in LC-MS/MS
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analysis of samples post-DNA digestion. Addition of
aminoguanidine (500mM) during digestion was found to
be essential to avoid overestimation of glycation adduct
analytes.
Incubation of calf thymus DNA
Calf thymus DNA (30mg) was suspended in 10mM
Tris/HCl, pH 7.4, containing 1mM EDTA and 0.2mM
DFOM (10ml, TED buﬀer) and dissolved by gentle agi-
tation over 24 h at 4C. The concentration of DNA was
checked by UV absorbance at 260 nm. Aliquots of DNA
(ﬁnal concentration 1.00mg/ml) were incubated in 50mM
potassium phosphate buﬀer, pH 7.4 and 37C, with
glyoxal or methylglyoxal (0.01–100mM), total volume
1.00ml, for 15 h with gentle shaking. DNA was then
precipitated with three volumes of 100% ethanol
(1ml; 4C), the precipitate sedimented by centrifugation
(2000g, 2min) and washed three times with 80% ethanol
(1ml; cold). Resultant pellets were dissolved in 1ml of
TED buﬀer and the concentration of DNA determined.
Control and modiﬁed DNA were digested as described
earlier and samples stored at 80C until LC-MS/MS
analysis.
Tumour cell lines with low and high expression
of glyoxalase 1
Two human tumour cell lines of relatively low Glo1
expression—NCI-H460 large cell lung carcinoma and
A549 alveolar basal epithelial carcinoma, and two
human tumour cell lines of relatively high Glo1 expres-
sion—MG63 osteosarcoma and NCI-H522 non-small cell
lung adenocarcinoma, as deﬁned by Tsuruo and
co-workers (14), were cultured as described earlier
(14,19,20). The level of Glo1 expression was conﬁrmed
by qPCR. Cells were grown to conﬂuence in 150 cm2
ﬂasks, trypsinized, re-suspended in media and centrifuged
at 400g for 5min. The medium was removed and the cells
were lysed in 10ml of Trizol (Invitrogen, Paisley, UK).
The RNA was then extracted using the chloroform
(0.2ml/1ml Trizol), 2-propanol (0.5ml/1ml of Trizol)
and 75% ethanol puriﬁcation. The extracted RNA was
dissolved in diethyl pyrocarbonate-treated water
(Ambion, Huntingdon, UK). cDNA was obtained by
two-step reverse transcription using SuperScript III
reverse transcriptase kit (Invitrogen) with ampliﬁcation
grade DNAse I (Sigma-Aldrich, Poole, UK) and random
nonamer primers (Sigma-Aldrich) as per manufacturer’s
instructions. Real time PCR was performed by the com-
parative CT method (21). The b-actin gene served as an
endogenous control. Sequences of the primers used were:
b-actin—forward AGAGCTACGAGCTGCCTGAC,
reverse TGAAGGTAGTTTCGTGGATGC; Glo1—
forward GCGCTCTCCAGAAAAGCTAC, reverse TG
CCATTGTGGTAACTCTGG.
Plasma and urine ultraﬁltrate
Healthy human subjects (recruited for the VITAGE
project) (22) were recruited at the Human Nutrition and
Metabolism Research and Training Center, Karl Franzens
University of Graz, Austria. The study protocols have
been approved by the local Ethics Committee and
written informed consent was obtained from all study
subjects. Venous blood samples were collected from all
study subjects in the fasting state and plasma prepared;
24 h urine collections were made for the VITAGE study.
Ultraﬁltrates were prepared by microspin ultraﬁltration of
plasma (10 kDa cut-oﬀ, 100ml) and urine (3 kDa cut-oﬀ,
100 ml), collecting ca. 50 ml ultraﬁltrate. Assessment of ana-
lytical recoveries was made by spiking plasma and urine
with 50 and 500 fmol adducts, respectively, prior to ultra-
ﬁltration and analysis of spiked and unspiked sample
ultraﬁltrates. Stable isotopic standards were added to the
ultraﬁltrates prior to analysis.
LC-MS/MS of nucleotide damage markers
For LC-MS/MS, the DNA digest and ultraﬁltrates (40 ml)
were spiked with 10 ml isotopic standard mixture contain-
ing 0.1 nmol [13C10,
15N5]dG, 1 pmol [
13C10,
15N5]8-OxodG,
0.73 pmol [13C10,
15N5]MGdG, 0.09 pmol
[13C10,
15N5]CEdG and 1.4 pmol [
13C10,
15N5]GdG.
LC-MS/MS was performed using an AcquityTM
UPLC-Quattro Premier tandem mass spectrometer with
a BEH C18 1.7 mm particle size, 2.1 100mm column.
The mobile phase was 0.1% formic acid with a linear
gradient of 0–10% acetonitrile from 2 to 10min and iso-
cratic 10% acetonitrile from 10 to15 min; the ﬂow rate was
0.25ml/min. After analysis, the column was washed with
50% acetonitrile containing 0.1% formic acid for 10min
and thereafter re-equilibrated with initial mobile phase for
10min. The column temperature was set to temperatures
in the range 4–30C as required.
Nucleoside adduct stability studies
The stability of GdG, MGdG and CEdG were
investigated in buﬀers used in DNA isolation and diges-
tion, autosampler storage and in urine for a 24 h collection
at ambient temperature. For stability in buﬀers, nucleo-
side adducts (100 pmol/ml) were incubated at 37C for
0–36 h in buﬀers: (i) 10mM ammonium acetate, pH 5.0,
with 100 mM DFOM; (ii) 10mM Tris/HCl, pH 7.4 with
1mM EDTA and 100 mM DFOM; and (iii) 10mM
ammonium bicarbonate, pH 9.0. After incubation, 20 ml
was mixed with isotopic standards (1 pmol
[13C10,
15N5]GdG, pmol [
13C10,
15N5]MGdG and 0.1 pmol
CEdG) and analysed by LC-MS/MS. For autosampler
stability, 10 pmol GdG, MGdG and CEdG in DNA di-
gestion buﬀer was analysed with and without storage at
4C in the Acquity autosampler for 24 h, with addition of
isotopic standards immediately prior to analysis. For
analyte stability in urine, aliquots of human urine were
analysed with and without storage at ambient temperature
(18C) for 24 h, with addition of isotopic standards imme-
diately prior to analysis.
DNA strand break assay
HL60 cells (1 105 cells/ml; 20ml) were incubated with
each of the treatments described. The cells were washed
twice with cold phosphate buﬀered saline, pH 7.4, and
ﬁxed in 1% (w/v) paraformaldehyde. The ﬁxed cells
were then stained using the terminal deoxynucleotidyl
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transferase-mediated dUTP-FITC nick-end labeling
(TUNEL) method (Apo-DirectTM Kit; Calibiochem)
for labeling DNA strand breaks. Cells were also stained
with propidium iodide for cell cycle analysis (23). Cells
within the normal cell cycle distribution pattern were
analysed for DNA strand breaks. Samples were analysed
using Becton-Dickinson FACSCalibur twin laser,
4-channel cytometry/cell sorter and the data processed
by FlowJo software v7.1.4 (Tree Star Inc.).
Statistical analysis
Limit of detection is analyte amount producing a signal/
noise ratio=3. Data are mean±SD for parametric data
and median (lower–upper quartile) for non-parametric
data. Signiﬁcance of diﬀerences of means or medians of
two independent groups of parametric or non-parametric
data was assessed by Student’s t-test and Mann–Whitney
U test, respectively. Signiﬁcance of diﬀerence in median of
two related groups was assessed by Wilcoxon signed rank
test. Correlation analysis was by the non-parametric
Spearmen method. Data in the study of degradation of
nucleotide adducts was ﬁtted to a single exponential
by least squares non-linear regression and half-life
deduced. Statistical analysis was performed by the SPSS
software, v15.
RESULTS
Assay of imidazopurinones by stable isotopic dilution
analysis LC-MS/MS
We prepared analytical standards and isotopomer internal
standards for GdG, MGdG, CEdG and 8-OxodG.
LC-MS/MS reversed phase chromatography with
multiple reaction monitoring of the analytes resolved the
analyte peaks from dG (Table 1). The chromatographic
peak for MGdG was unexpectedly broad with column
temperature at 30C (Figure 2a). On cooling the column
to 10C, the MGdG peak was partially resolved into a
three-component peak; no further improvement in peak
resolution was achieved at lower column temperatures.
This complex peak structure of MGdG is attributed to
resolution of structural and stereoisomers; the R/
S-epimers of CEdG—CEdGA and CEdGB, were also
resolved (Figure 2b). This characteristic chromatographic
proﬁle was used in subsequent analysis (Figure 2c–h).
Fragment ion scan analysis (collision energy ramp 12–
30 eV) showed common fragments of the imidazopurinone
base for all three peak components: m/z (neutral fragment
loss): 206 (-H2O), 178 (-H2CO2) and 152 (-methylglyoxal);
the 178 fragment was also a dominant in the fragment
ion scan of CEdGA and CEdGB, as expected for decarb-
oxylation of the N2-(1-carboxyethyl) moiety. The two
MGdG component peaks eluting ﬁrst had similar 178/
224 fragment ion intensity ratios that were higher than
for ﬁnal peak component (0.82 and 0.86 versus 0.50). In
the 1H NMR spectrum of MGdG in d6-DMSO there were
minor peaks duplicating the resonances for 5-NH, 6/
7-methyl and 7/6-H protons in integral ratio 86: 14—
Supplementary Data, Figure 1. There was no coupling
resolved for 5-NH and 6-H protons in GdG and hence
resolution of coupling of 5-NH and 6-H protons in the
7-methyl isomer of MGdG was not expected. Shapiro
et al. (2) found the 6-methyl isomer is the major
product; the major resonances (86%) are therefore
assigned to this 6-methyl isomer. The three-component
peak of the MGdG chromatogram had two major peaks
representing ca. 86% of the peak area—attributed to
6-methyl stereoisomers, and the minor component of
longest retention time representing ca. 14% of the peak
area—attributed to 7-methyl stereoisomers. Application
of LC-MS/MS for quantiﬁcation of these adducts
produced an analytical method of linear response to
analyte, high sensitivity and recovery and low variability
(Figure 2i–l). For GdG, MGdG, CEdG and 8-OxodG,
limits of detection were 0.8, 2.5, 2.2 and 0.7 fmol; analyt-
ical recoveries were 104, 97, 98 and 99%, respectively, and
coeﬃcients of variation 2–7% in the working analyte
range for DNA digests. The high analytical recoveries
indicate all four analytes were stable during the DNA hy-
drolysis procedure. There was no signiﬁcant loss of
analyte during working storage (autosampler at 4C for
24 h) and over 24 h urine collection at room temperature.
Stability of imidazopurinones
The stability of imidazopurinones at 37C was
investigated in ammonium acetate (pH 5.0) and Tris/
HCl (pH 7.4) buﬀers used in DNA digestion and in
ammonium bicarbonate buﬀer (pH 9.0) used by others
for pre-analytic processing. GdG had half-lives at 37C
of 230±6h at pH 5.0, 16.1±0.4 h at pH 7.4 and <1 h
at pH 9. MGdG was less stable than GdG with half-lives
at 37C of 38.1±3.2 h at pH 5.0, 12.0±0.3 h at pH 7.4
and <0.2 h at pH 9 (Figure 3a and b). Addition of the
methylglyoxal scavenger aminoguanidine (500mM) (24) to
incubations for the study of MGdG degradation did not
prevent the formation of CEdG, suggesting that the
MGdG interconversion occurs mainly by intramolecular
rearrangement from the 6-methylimidazopurinone isomer.
The high instabilities of GdG and MGdG in ammonium
bicarbonate buﬀer at pH 9 explains why GdG and MGdG
have been overlooked and markedly underestimated in
previous studies employing high pH processing in DNA
digests (25,26).
Table 1. Detection of imidazopurinones and related
deoxyguanosine-derived adducts by liquid chromatography-tandem
mass spectrometry multiple reaction monitoring
Analyte Rt
(min)
Molecular> fragment
ion transition
(Da)
Collision
energy
(eV)
Cone
voltage
(V)
dG 7.3 268.1> 152.0 37 12
GdG 6.7 325.7> 209.9 12 12
MGdGa 7.4, 7.8 and 8.4 340.0> 224.0 12 11
CEdGa 9.8 and 11.1 340.0> 224.0 12 11
8-OxodG 8.4 283.8> 168.0 12 12
The neutral fragment loss was 2-dehydro-2-deoxyribose.
aMultiple retention times are shown for adduct structural and stereo-
isomers isomers.
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Imidazopurinone adducts formed during the reaction of
DNA with glyoxal and methylglyoxal
We studied the formation of imidazopurinone and
CEdG adducts in the reaction of calf thymus DNA
with glyoxal and methylglyoxal. Calf thymus DNA
had ca. 3, 6 and 0.02 adducts of GdG, MGdG
and CEdG per 106 nucleotides as supplied. Incubation
with 0.01–100mM glyoxal increased the content of
GdG from 3 to 757 adducts per 106 nt. Similar incubation
with methylglyoxal increased the MGdG content from
6 to 433 adducts per 106 nt and the CEdG content from
0.02 to 5 adducts per 106 nt. The MGdG/CEdG adduct
ratio was 30–300 over the concentration range, indicating
that imidazopurinone MGdG was the major adduct
formed by modiﬁcation of DNA with methylglyoxal
(Figure 3c and d).
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Figure 2. Detection of imidazopurinones and related deoxyguanosine-derived adducts by liquid chromatography-tandem mass spectrometry multiple
reaction monitoring. (a and b) LC-MS/MS analysis of isobaric MGdG and CEdG adducts (10 pmol) at column temperature 30 and 10C, respect-
ively. (c–h) Detection of deoxyguanosine-derived adducts in nuclease digests of human mononuclear leukocyte DNA. The asterisk in (d, e, g and h)
indicates formation of GdG and 8-OxodG from dG in the sample in the electrospray ionization source of the mass spectrometer. Calibration curves
of peak area ratio versus analyte (pmol). (i) GdG: regression equation peak area ratio= (0.98±0.02)GdG+ (0.02±0.01); R2=0.996. (j) MGdG:
regression equation peak area ratio= (1.38±0.04)MGdG+ (0.04±0.02); R2=0.995. (k) CEdG: regression equation peak area
ratio= (11.4±0.2)CEdG+(0.14±0.09); R2=0.999. (l) 8-OxodG: regression equation peak area ratio= (0.72±0.03) 8-OxodG+
(0.01±0.01); R2=0.994. Amount of stable isotopic standard added was: 1.0 pmol [13C10,
15N5]GdG, 0.73 pmol [
13C10,
15N5]MGdG, 0.09 pmol
[13C10,
15N5]CEdG and 1.4 pmol [
13C10,
15N5]8-OxodG. Experimental details are given in the ‘Materials and Methods’ section.
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Imidazopurinone adducts in cellular DNA and link to
DNA strand breaks
To assess if imidazopurinones were the dominant adduct
of physiological DNA damage and had functional links,
we determined levels of imidazopurinones, CEdG and
8-OxodG in cellular DNA in vitro and in vivo, and
assessed related frequency of DNA strand breaks. For
human leukaemia 60 (HL60) cells cultured in vitro,
DNA adducts per 106 nt were: GdG 2.67±0.63, MGdG
18.2±6.5, CEdG 1.33±1.12 and 8-OxodG 1.48±0.39.
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Figure 3. Imidazopurinone stabilities and adducts of DNA in vitro and in vivo and link to DNA strand breaks. (a and b) Stability of GdG and
MGdG in DNA isolation buﬀer (10mM Tris/HCl, pH 7.4 with 1mM EDTA and 100mM DFOM), pH 7.4 and 37C. Data are mean±SD of four
determinations with the exponential decay curve of best ﬁt shown. (c and d) Formation of nucleotide AGEs by incubation of calf thymus DNA with
glyoxal and methylglyoxal, respectively. Data are mean±SD (n=3).Solid bars, imidazopurinone adduct; hollow bars, CEdG. (e and f) Increased
MGdG adduct and DNA strand breaks in HL60 cells exposed to increased exogenous and endogenous methylglyoxal. Key: HL60 cells (1 105/ml;
3 107) incubated for 2 h with no further addition (control), 524mM methylglyoxal (MG), 500 mM aminoguanidine (AG) and 524 mM methylglyoxal
with 500mM aminoguanidine (MG+AG). A similar incubation for 24 h was with addition of 10 mM BBGD (Glo1 inhibitor). Data are mean±SD
with n and P-values (Student’s t-test) given.
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Incubation of HL60 cells with 524mM methylglyoxal
(2median growth inhibitory GC50 concentration) (27)
for 2 h increased MGdG content of DNA 2-fold without
signiﬁcant increase in other adducts and increased DNA
strand breaks by 7-fold. The increase in MGdG and DNA
strand breaks was prevented by co-incubation with the
dicarbonyl scavenger aminoguanidine. Incubation of
HL60 cells with the cell permeable Glo1 inhibitor,
BBGD (10 mM—which is twice the median growth inhibi-
tor concentration GC50) (15) increased the DNA content
of MGdG by 5-fold and DNA strand breaks by 27-fold.
The DNA strand breaks content of HL60 cells correlated
with MGdG content of DNA; r=0.76, P=0.0015,
Spearman (Figure 3e and f).
Imidazopurinone adducts of cellular DNA and related
nucleosides in plasma and urine in vivo
For estimation of imidazopurinone adducts in cellular
DNA in vivo, we analysed adducts of DNA extracted
from peripheral human mononuclear leukocytes from
healthy human subjects. DNA adduct contents were
(adducts per 106 nt; n=3): GdG 2.11±0.74, MGdG
8.73±2.41, CEdG 1.03±0.38 and 8-OxodG
2.79±0.64. To assess the release from DNA and excre-
tion of imidazopurinones and 8-OxodG in human subjects
in vivo, we determined the concentrations of related nu-
cleoside adducts in plasma and urine of healthy human
subjects. Analytical recoveries for estimation of GdG,
CEdG MGdG and 8-OxodG were: in plasma—93±5%,
96±8%, 99±4% and 82±14%, respectively; and in
urine were 85±7, 96±5, 98±6 and 87±12 (n=4).
Median plasma concentrations of GdG, CEdG, MGdG
and 8-OxodG in healthy human subjects were 0.066,
0.144, 0.338 and 0.076 nM, respectively. Median urinary
excretion rates of GdG, CEdG MGdG and 8-OxodG and
in healthy human subjects were 0.23, 0.90, 2.63 and 0.90
nmol/24 h, respectively. Signiﬁcance testing indicated the
plasma concentration and urinary excretion of dG adducts
was in the order: MGdG> 8-oxodG&CEdG> GdG
(Figure 4a and b). Plasma and urinary levels of MGdG
were, therefore, 4- and 3-fold higher than 8-OxodG in
plasma and urine, respectively. For urinary excretions,
GdG correlated positively with urinary MGdG
(r=0.58, P< 0.01) and CEdG correlated positively with
GdG (r=0.64, P< 0.001) and MGdG (r=0.56,
P< 0.01).
Imidazopurinone adducts in cellular DNA of tumour cell
lines with low and high expression of glyoxalase-1
Imidazopurinone, CEdG and 8-OxodG adduct contents
were determined in DNA of two human cell lines of rela-
tively low Glo1 expression—NCI-H460 large cell lung car-
cinoma and A549 alveolar basal epithelial carcinoma and
two human cell lines of relatively high Glo1 expression—
MG63 osteosarcoma and NCI-H522 non-small cell lung
adenocarcinoma, as deﬁned by Tsuruo and co-workers
(14) and conﬁrmed by qPCR. Relative Glo1 expression
relative to b-actin and normalized to the expression in
NCI-H460 cells was: NCI-H460 cells, 1.0; A549 cells,
6.6; MG63, 10.6 and NCI-H522 cells, 33.2. The median
contents of MGdG and 8-oxodG in DNA were increased
signiﬁcantly in cell lines with relatively high Glo1 expres-
sion. For all cell lines, MGdG content of DNA correlated
positively with GdG adduct content (r=0.82, P< 0.01)
and 8-OxodG content (r=0.87, P< 0.001) but not with
CEdG adduct content of DNA (n=12) (Table 2).
DISCUSSION
In this study we found that modiﬁcation of DNA by
physiological dicarbonyls gives rise to quantitatively im-
portant steady-state levels of dG-derived adducts in
cellular DNA in vitro and in vivo—imidazopurinone de-
rivatives. Imidazopurinone contents of DNA were
markedly higher than that of other physiological alde-
hydes—4HNE, malondialdehyde and others (8). Hence,
measurement of imidazopurinone adducts and nucleosides
in body ﬂuids may be valuable biomarkers of quantitative
and functionally important DNA damage in vivo.
Initial approaches to develop methods to quantify nu-
cleotide adducts formed by glyoxal and methylglyoxal in
DNA involved 32P-labelling studies of DNA digests (28)
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and immunoassay (4). Stable isotopic dilution analysis
LC-MS/MS was applied successfully herein for assay of
imidazopurinones, related CEdG and 8-OxodG concur-
rently. The high speciﬁcity and sensitivity of LC-MS/MS
makes this the preferred method for DNA damage marker
quantitative analysis. For relatively unstable nucleotide
adducts such as the imidazopurinones, it was necessary
to devise a pre-analytic processing protocol to minimize
formation, interconversion and degradation of adducts.
Our method involves use of acid nuclease and phosphat-
ase, metal ion chelator throughout and the dicarbonyl
scavenger aminoguanidine and thereby avoids artifactual
formation and minimizes loss of adducts in pre-analytic
processing. Investigation of the stabilities of
imidazopurinones indicated previous use of high pH and
prolonged elevated temperatures in DNA digestion proto-
cols likely led to the degradation of labile GdG and
MGdG. Hence, the quantitative importance of
imidazopurinone adducts has been overlooked. The sta-
bility of GdG in phosphate-buﬀered saline, pH 7.4 and
37C, has been reported previously and was ca. 12 h
(10). This was repeated herein and the half-life was
11.4±0.4 h—lower than for the determination in
Tris/HCl–EDTA–DFOM buﬀer (16.1±0.4 h).
Phosphate buﬀer—particularly the conjugate base
HPO24 —likely de-stabilizes imidazopurinones by
deprotonation. The LC-MS/MS method also resolved
the adducts from dG chromatographically to avoid inter-
ference from formation of adducts by partial degradation
of dG during electrospray ionization.
CEdG was determined by immunoassay previously in
human urine of normal healthy human subjects with esti-
mates in the range 3.4–344 pmol/mg creatinine and
median of ca. 30 pmol/mg creatinine (29). Estimation
herein by LC-MS/MS gave median value equivalent to
0.55 pmol/mg creatinine suggesting that immunoassay
overestimated urinary CEdG by ca. 50-fold. Similar over-
estimation with immunoassay of 8-OxodG was reported
(30). This is likely caused by interference due to imperfect
epitope speciﬁcity of the monoclonal antibody used and
analyte formation from other sample components during
pre-analytic sample processing. A recent independent
estimate by Synold et al. (9) of CEdG content of
tumours using stable isotopic dilution analysis LC-MS/
MS found ca. 1.5 adducts per 106 dG which is similar to
the estimate in tumour cell lines with high Glo1 expression
herein. The sample processing procedures used in
pre-analytic processing, however—such as DNA heated
to 95C, samples incubated at pH 8 and 50C for 12–
18 h and release of adducts from sample clean-up
columns with 3% ammonium hydroxide—can be judged
as inappropriate for imidazopurinone detection from
adduct stability studies herein. Moreover, they risk
compromising even CEdG detection by artifactual forma-
tion of analyte by sample component degradation to
analyte under these conditions of high temperature and
pH. Similar compromized analysis of CEdG applies to
the study of Yuan et al. (3) where DNA hydrolysates
were incubated for 4 h with addition Tris–HCl buﬀer,
pH 8.9 and 37C to the hydrolysate (ﬁnal pH ca. 8.4)
which is expected to lead to loss of MGdG with formation
of CEdG—see above. Incubation of MGdG under these
conditions produced complete loss of analyte (data not
shown).
Imidazopurinone adducts of dG are formed by reactiv-
ity of glyoxal derivatives with the N2-amino group of dG
with cyclic attachment to ring N1. Similar reactivity of the
exocyclic N2-amino group of dG with aldehydes such as
4-hydroxynonenal (4HNE) has been reported (31). For
methylglyoxal, this forms a mixture of 6- and 7-methyl
isomers. The major isomer was the 6-methyl stereoisomer.
Stereoisomerism of imidazopurinones provided a charac-
teristic chromatographic proﬁle of MGdG and CEdG.
Formation of imidazopurinones produces two chiral
centres at positions 6 and 7, giving rise to four stereoiso-
mers of GdG (not resolved chromatographically) and
eight structural and stereoisomers of MGdG (partially
resolved). Chromatographic resolution of isomers of
MGdG and CEdG has been reported previously (28,32).
Relative detection response peak areas for component
peaks for MGdG and CEdG were not signiﬁcantly diﬀer-
ent for all test and standards samples, suggesting isomer
distribution is constant in standard and test samples
and hence quantitation was not compromized.
Mechanistically, CEdG is also likely formed by the
reaction encounter of methylglyoxal monohydrate with
dG. CEdG may be formed by glycating agents other
than methylglyoxal—ascorbic acid and glucose, for
example, involving complex degradation and fragmenta-
tion reactions (33,34). Alternative sources of CEdG as well
as diﬀerent rates of repair of CEdG and MGdG lesions
may also contribute to the ratio of CEdG/MGdG being
higher in cellular DNA than in DNA modiﬁed by
methylglyoxal in cell-free system.
Imidazopurinone adducts of DNA were associated with
DNA breaks herein. Methylglyoxal modiﬁcation of DNA
is also linked to increased mutation frequencies (35). It
may be linked to mutagenesis in ageing, diabetes, renal
failure and other disorders associated with increased
levels of dicarbonyl metabolites (4,11,36). Increased for-
mation of CEdG was detected in human melanoma
WM-266-4 cells incubated with exogenous methylglyoxal
and with high glucose concentration—although part may
have been formed by degradation of MGdG in
pre-analytic processing (3). CEdG was also found to be
mutagenic and induced DNA strand breaks (37). This
Table 2. Imidazopurinone and related DNA adducts of human
tumour cells lines with low and high expression of glyoxalase 1
Glyoxalase 1 expression
Analyte Low High
GdG 1.01 (0.23–1.65) 1.69 (1.56–2.71)
MGdG 1.10 (0.69–1.83) 10.43 (4.32–13.47)**
CEdG 0.49 (0.43–0.69) 0.77 (0.19–1.77)
8-OxodG 1.08 (0.77–1.58) 8.10 (6.80–15.50)**
Low Glo1 expression cell lines were NCI-H460 and A549, and high
glyoxalase 1 cell lines were MG63 and NCI-H522.
Data are median (upper–lower quartile); adducts per 106 nt.
**P< 0.01 (Mann–Whitney U-test).
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occurred, however, at engineered CEdG contents of DNA
over 1000-fold higher than found in cellular DNA physio-
logically. The eﬀect of CEdG on DNA integrity and mu-
tagenic activity at physiological adduct levels is unknown.
MGdG content of DNA was increased by exposure of
cells to exogenous methylglyoxal and by increasing en-
dogenous methylglyoxal by inhibition of Glo1 with S-p-
bromobenzylglutathione delivered intracellularly by
BBGD. The latter was more eﬀective than the former
probably because an active Glo1 in the cytosol intercepts
eﬀectively methylglyoxal diﬀusing from the culture
medium to the nucleus. BBGD produced a profound
increase of MGdG adducts in cellular DNA; it also over-
comes MDR in human tumours associated with
overexpression of Glo1 (14).
The ﬁnding of increased MGdG content of DNA in
human tumour cell lines with high relatively expression
of Glo1 linked to MDR was counterintuitive. Increased
expression and activity of Glo1, given a similar ﬂux of
methylglyoxal formation in cells with similar glycolytic
activities, is expected to lead to decreased levels of
MGdG. The tumour cell lines studied with high Glo1
expression [for example MG63 cells (19)] are known,
however, to have high glycolytic activities relative to
cell lines with low Glo1 expression and activities [for
example A549 cells (20)]. We propose, therefore, that
increased Glo1 expression is an imperfect adaptation of
tumour cells with relatively high glycolytic activity to
suppress increased level of methylglyoxal formed and
prevent potential cytotoxicity. The concentration of
methylglyoxal in cells is in the range 0.5–2 mM increasing
2–3-fold further in some cells in hyperglycaemia and
does not induce acute cytotoxicity (38,39). High concen-
trations of exogenous methylglyoxal (200–500 mM)
induced growth arrest and toxicity in tumour cells (27)
but lower concentrations (10–20 mM) induced apoptosis
in some cell types (40). Increased ﬂux of formation of
methylglyoxal in tumour cells without increased activity
of Glo1 or other detoxiﬁcation activity may induce cyto-
toxicity. High expression and activity of Glo1 may be
thereby permissive of growth for tumours with high glyco-
lytic activity and unavoidable concomitant increased ﬂux
of methylglyoxal formation. The correlation of MGdG
and 8-OxodG content of DNA in tumour cell lines
might be expected since cells exposed to increased en-
dogenous levels of methylglyoxal—as in the nematode
Caenorhabditis elegans in old age—show increased modi-
ﬁcation of mitochondrial proteins by methylglyoxal with
related increased formation of reactive oxygen species and
oxidative damage (41). This is reported in the tumour cells
herein by increased DNA content of 8-OxodG. The lack
of correlation of MGdG and CEdG contents of DNA
may indicate signiﬁcant contribution of glycating agents
other than methylglyoxal to formation of CEdG—see
above.
In conclusion, from their high relative content in DNA
and the link to functional eﬀects, imidazopurinones
derived from glyoxal and methylglyoxal are of likely
pathogenic and diagnostic as well as, potentially, thera-
peutic signiﬁcance—particularly in Glo1-linked MDR
tumours.
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